Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.

Published on Dec 28, 2017in OncoImmunology5.869
· DOI :10.1080/2162402X.2017.1421889
Francesca Tosetti21
Estimated H-index: 21
,
Roberta Venè22
Estimated H-index: 22
+ 7 AuthorsMaria Raffaella Zocchi42
Estimated H-index: 42
Sources
Abstract
ABSTRACTShedding of ADAM10 substrates, like TNFα, MICA or CD30, is reported to affect both anti-tumor immune response and antibody-drug-conjugate (ADC)-based immunotherapy. Soluble forms of these molecules and ADAM10 can be carried and spread in the microenvironment by exosomes released by tumor cells. We reported new ADAM10 inhibitors able to prevent MICA shedding in Hodgkin lymphoma (HL), leading to recognition of HL cells by cytotoxic lymphocytes.In this paper, we show that the mature bioactive form of ADAM10 is released in exosome-like vesicles (ExoV) by HL cells and lymph node mesenchymal stromal cells (MSC). We demonstrate that ADAM10 inhibitors are released in ExoV by MSC or HL cells, endocytosed by bystander cells and localized in the endolysosomal compartment in HL MSC. ExoV released by HL cells can enhance MICA shedding by MSC, while ExoV from MSC induce TNFα or CD30 shedding by HL cells. Of note, ADAM10 sheddase activity carried by ExoV is prevented with the ADAM10 inhibitors LT4 and CAM29, pre...
📖 Papers frequently viewed together
30 Citations
30 Citations
4 Citations
References43
Newest
#1Sven BorchmannH-Index: 10
Last. Andreas EngertH-Index: 105
view all 3 authors...
PURPOSE OF REVIEW: After presenting the current treatment recommendations for early-stage Hodgkin lymphoma, we give an overview on recently published clinical trials in this setting. Furthermore, the potential influence of current trials on the treatment of early-stage Hodgkin lymphoma and integration of newly emerging drugs into treatment protocols will be discussed. RECENT FINDINGS: Trials attempting treatment de-escalation and omission of radiotherapy on the basis of early interim PET-scans h...
19 CitationsSource
#2Caterina CamodecaH-Index: 12
Last. Alessandro PoggiH-Index: 56
view all 10 authors...
ABSTRACTHodgkin lymphoma (HL) resistant to conventional therapies is increasing, making of interest the search for new schemes of treatment. Members of the “A Disintegrin And Metalloproteases” (ADAMs) family, mainly ADAM10 or ADAM17, have been proposed as therapeutic targets in solid tumors and some ADAMs inhibitors have been shown to exert antitumor effects. We have previously described an overexpression of ADAM10 in HL, together with increased release of NKG2D ligands (NKG2D-L) and reduced act...
30 CitationsSource
#1Hinrich P. Hansen (University of Cologne)H-Index: 28
#2Ahmad TradH-Index: 12
Last. Elke Pogge von StrandmannH-Index: 29
view all 18 authors...
// Hinrich P. Hansen 1 , Ahmad Trad 2 , Maria Dams 1 , Paola Zigrino 3 , Marcia Moss 4 , Maximilian Tator 1 , Gisela Schon 1 , Patricia C Grenzi 1 , Daniel Bachurski 1 , Bruno Aquino 5 , Horst Durkop 6 , Katrin S Reiners 1 , Michael von Bergwelt-Baildon 1 , Michael Hallek 1 , Joachim Grotzinger 2 , Andreas Engert 1 , Adriana F Paes Leme 5 , Elke Pogge von Strandmann 1 1 Department of Internal Medicine I, University of Cologne, Cologne, Germany 2 Department of Biochemistry, University Kiel, Kiel,...
32 CitationsSource
#1Caterina CamodecaH-Index: 12
#2Elisa Nuti (UniPi: University of Pisa)H-Index: 25
Last. Armando Rossello (UniPi: University of Pisa)H-Index: 28
view all 9 authors...
Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10, h...
29 CitationsSource
#1Peter J. Noy (University of Birmingham)H-Index: 15
#2Jing Yang (University of Birmingham)H-Index: 5
Last. Michael G. Tomlinson (University of Birmingham)H-Index: 28
view all 9 authors...
A disintegrin and metalloprotease 10 (ADAM10) is a ubiquitously expressed transmembrane metalloprotease that cleaves the extracellular regions from its transmembrane substrates. ADAM10 is essential for embryonic development and is implicated in cancer, Alzheimer, and inflammatory diseases. The tetraspanins are a superfamily of 33 four-transmembrane proteins in mammals, of which the TspanC8 subgroup (Tspan5, 10, 14, 15, 17, and 33) promote ADAM10 intracellular trafficking and enzymatic maturation...
61 CitationsSource
#1Shoko Nakayama (Osaka Medical College)H-Index: 8
#2Taiji Yokote (Osaka Medical College)H-Index: 12
Last. Toshiaki Hanafusa (Osaka Medical College)H-Index: 66
view all 12 authors...
16 CitationsSource
#1Marie Lundholm (Umeå University)H-Index: 13
#2Mona Schröder (Umeå University)H-Index: 2
Last. Pernilla Wikström (Umeå University)H-Index: 37
view all 7 authors...
Tumor-derived exosomes, which are nanometer-sized extracellular vesicles of endosomal origin, have emerged as promoters of tumor immune evasion but their role in prostate cancer (PC) progression is poorly understood. In this study, we investigated the ability of prostate tumor-derived exosomes to downregulate NKG2D expression on natural killer (NK) and CD8+ T cells. NKG2D is an activating cytotoxicity receptor whose aberrant loss in cancer plays an important role in immune suppression. Using flo...
156 CitationsSource
#1Sonia Pahwa (OU: University of Oklahoma)H-Index: 5
#2Maciej Stawikowski (Torrey Pines Institute for Molecular Studies)H-Index: 10
Last. Gregg B. Fields (Torrey Pines Institute for Molecular Studies)H-Index: 68
view all 3 authors...
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a zinc-dependent type-I transmembrane metalloproteinase involved in pericellular proteolysis, migration and invasion. Numerous substrates and binding partners have been identified for MT1-MMP, and its role in collagenolysis appears crucial for tumor invasion. However, development of MT1-MMP inhibitors must consider the substantial functions of MT1-MMP in normal physiology and disease prevention. The present review examines the plethora of MT1...
59 CitationsSource
#1Mark G. Waugh (UCL: University College London)H-Index: 20
Abstract This article describes a procedure to prepare a raft-like intracellular membrane fraction enriched for the trans-Golgi network (TGN) and endosomal compartments. The initial step in this technique involves cell disruption by homogenization, followed by clearance of the plasma membrane, late endosomes, mitochondria and the endoplasmic reticulum by differential sedimentation. Carbonate treatment, sonication and sucrose density-gradient ultracentrifugation are subsequently used to isolate t...
14 CitationsSource
#1Guranda Chitadze (CAU: University of Kiel)H-Index: 7
#2Marcus Lettau (CAU: University of Kiel)H-Index: 20
Last. Dieter Kabelitz (CAU: University of Kiel)H-Index: 65
view all 11 authors...
The interaction of the MHC class I-related chain molecules A and B (MICA and MICB) with the corresponding natural killer group 2, member D (NKG2D) receptor triggers cytotoxic effector activity of natural killer cells and certain T-cell subsets and provides a costimulatory signal for cytokine production. Thus, the presence of MICA/B on transformed cells contributes to tumor immunosurveillance. Consequently, the proteolytic cleavage of MICA/B is regarded as an important immune escape mechanism of ...
118 CitationsSource
Cited By18
Newest
Mesenchymal stem cells (MSCs) are the most exploited stem cells with multilineage differentiation potential and immunomodulatory properties. Numerous lines of findings have reported their successful applications in a multitude of inflammatory conditions and immune disorders. However, it is currently discovered that these effects are mainly mediated in a paracrine manner by MSC-exosomes. Moreover, MSC-exosomes have been implicated in a wide variety of biological responses including immunomodulati...
Source
#1Roberta Pece (UniGe: University of Genoa)H-Index: 2
#2Sara Tavella (UniGe: University of Genoa)H-Index: 17
Last. Cristina D'ArrigoH-Index: 19
view all 16 authors...
Shedding of A Disintegrin And Metalloproteinases (ADAM10) substrates, like TNFα or CD30, can affect both anti-tumor immune response and antibody-drug-conjugate (ADC)-based immunotherapy. We have published two new ADAM10 inhibitors, LT4 and MN8 able to prevent such shedding in Hodgkin lymphoma (HL). Since tumor tissue architecture deeply influence the outcome of anti-cancer treatments, we set up new three-dimensional (3D) culture systemsto verify whether ADAM10 inhibitors can contribute to, or en...
Source
Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled receptors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highligh...
2 CitationsSource
#1Poonam Nagpal (Kean University)H-Index: 4
Last. Niraj Lodhi (TTUHSC: Texas Tech University Health Sciences Center)H-Index: 12
view all 3 authors...
Background Classical Hodgkin lymphoma (cHL) is a unique lymphoid malignancy with a tumor microenvironment (TME) consisting of a small number of neoplastic-Hodgkin and Reed-Sternberg (H-RS) cells ( 90%). The TME of cHL critically depends on immune cells to support tumor growth as H-RS cells cannot survive and proliferate in isolation. Recent findings Programmed cell death protein 1 (PD-1) ligand expressed on H-RS cells inhibits the clearance of tumor by causing T-cell exhaustion. Nivolumab and pe...
2 CitationsSource
#1Dorian ForteH-Index: 8
#2Martina BaroneH-Index: 3
Last. Lucia CataniH-Index: 29
view all 4 authors...
Blood cancers are a heterogeneous group of disorders including leukemia, multiple myeloma, and lymphoma. They may derive from the clonal evolution of the hemopoietic stem cell compartment or from the transformation of progenitors with immune potential. Extracellular vesicles (EVs) are membrane-bound nanovesicles which are released by cells into body fluids with a role in intercellular communication in physiology and pathology, including cancer. EV cargos are enriched in nucleic acids, proteins, ...
1 CitationsSource
#1Jihane Khalife (City of Hope National Medical Center)H-Index: 10
#2James F. Sanchez (City of Hope National Medical Center)H-Index: 11
Last. Flavia Pichiorri (City of Hope National Medical Center)
view all 3 authors...
Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states. In hematological malignancies, tumor-derived EVs are critical players in mediating intercellular communications through the transfer of genetic materials and proteins between neoplastic cells themselves and to several components of the bone marrow microenvironment, rendering the latter a "stronger" niche supporting cancer cell proliferation, drug res...
5 CitationsSource
#1Namdoo Kim (KNU: Kongju National University)H-Index: 6
#2Hyuck Jin Lee (KNU: Kongju National University)H-Index: 14
Various amyloidogenic proteins have been suggested to be involved in the onset and progression of neurodegenerative diseases (ND) such as Alzheimer's disease (AD) and Parkinson's disease (PD). Particularly, the aggregation of misfolded amyloid-β and hyperphosphorylated tau and α-synuclein are linked to the pathogenesis of AD and PD, respectively. In order to care the diseases, multiple small molecules have been developed to regulate the aggregation pathways of these amyloid proteins. In addition...
1 CitationsSource
#1Esther E.E. Drees (VU: VU University Amsterdam)H-Index: 3
#2D. Michiel Pegtel (VU: VU University Amsterdam)H-Index: 27
B cell lymphomas are heterogeneous malignancies of hematological origin with vastly different biology and clinical outcomes. Histopathology of tissue biopsies and image-based assessment guide clinical decisions. Given that tissue biopsies cannot be frequently repeated and will not inform on systemic responses to the treatment, more accessible biomarkers, such as circulating miRNAs, are considered. Aberrant miRNA expression in lymphoma tissues and ongoing immune reactions may lead to miRNA altera...
7 CitationsSource
#1Armando Rossello (UniPi: University of Pisa)H-Index: 28
#2Alexander Steinle (Goethe University Frankfurt)H-Index: 55
Last. Maria Raffaella ZocchiH-Index: 42
view all 4 authors...
Source
#2Francesca TosettiH-Index: 21
Last. Alessandro PoggiH-Index: 56
view all 4 authors...
Both natural and synthetic nanoparticles have been proposed as drug carriers in cancer treatment, since they can increase drug accumulation in target tissues, optimizing the therapeutic effect. As an example, extracellular vesicles (EV), including exosomes (Exo), can become drug vehicles through endogenous or exogenous loading, amplifying the anticancer effects at the tumor site. In turn, synthetic nanoparticles (NP) can carry therapeutic molecules inside their core, improving solubility and sta...
6 CitationsSource